Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 on Markers of Pulmonary Inflammation in Subjects With Moderate to Severe COPD

NCT00634413 is registered in ClinicalTrials.gov with Pulmagen Therapeutics as lead sponsor.

NCT NCT00634413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00634413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 on Markers of Pulmonary Inflammation in Subjects With Moderate to Severe COPD
Lead sponsor
Pulmagen Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
January 31, 2009
Enrollment
91 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease